+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast to 2030- Product Image
Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015053
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allogeneic Stem Cells Market grew from USD 328.34 million in 2024 to USD 393.14 million in 2025. It is expected to continue growing at a CAGR of 19.01%, reaching USD 933.17 million by 2030.

Unveiling the Promise of Allogeneic Stem Cells

The field of allogeneic stem cells has emerged as a frontier of regenerative medicine, promising transformative therapies across a range of diseases and injuries. Unlike autologous approaches that rely on a patient’s own cells, allogeneic treatments leverage donor-derived cells, offering the potential for off-the-shelf availability, consistent quality, and scalable production. This executive summary distills the core trends, drivers, and challenges reshaping this dynamic market.

In recent years, advancements in cell expansion technologies and improved understanding of immunomodulation have elevated the commercial viability of allogeneic products. As research moves from proof-of-concept to late-stage clinical trials, industry stakeholders are positioning themselves to capture growth opportunities across hematology, immunotherapy, orthopedics, and beyond. This introduction establishes the context for deeper analysis of regulatory shifts, tariff impacts, user segmentation, geographic diversities, competitive forces, and strategic imperatives that will define the coming years.

Emerging Breakthroughs Reshaping Allogeneic Stem Cell Applications

Breakthroughs in cell engineering and biomanufacturing have catalyzed a profound shift in how allogeneic stem cells are developed, produced, and delivered. Gene editing tools have enabled precise immunomodulatory enhancements, reducing the risk of rejection and improving therapeutic efficacy. Simultaneously, closed-system bioreactors and automated expansion platforms have increased yield and lowered per-unit cost, making large-scale production more attainable for both established players and emerging developers.

Regulatory bodies worldwide have signaled accelerated pathways for advanced therapies, granting conditional approvals based on compelling safety and preliminary efficacy data. This evolving framework has spurred greater industry investment into pivotal trials and post-market surveillance, fostering a more predictable commercial environment. At the same time, strategic alliances between biotechs, contract development and manufacturing organizations, and academic centers have reinforced supply chains and broadened distribution capabilities. These collective shifts underscore an inflection point where scientific promise converges with commercial readiness.

Decoding the 2025 US Tariff Impact on Allogeneic Stem Cell Trade

In early 2025, the United States implemented updated tariff schedules affecting key raw materials and ancillary components integral to allogeneic stem cell production. The revised duties on certain biological reagents and single-use bioprocessing kits have increased input costs by an average of 5 to 8 percent. Manufacturers relying on cross-border supply chains have responded with a mix of strategic sourcing realignments and partial cost absorption to maintain competitive pricing for end users.

These tariff adjustments have had cascading effects on procurement strategies. Organizations have accelerated qualification of domestic suppliers where possible and invested in backward integration for critical media and consumables. Meanwhile, some developers have explored tariff mitigation through regional free trade agreements and bonded warehousing solutions. Although the immediate burden has been modest for large-scale producers, emerging companies with leaner capital structures have felt more pronounced pressure, prompting collaborative purchasing consortia and shared vendor agreements to spread costs. Overall, the 2025 tariff landscape has reinforced the importance of supply chain agility and diversified sourcing in safeguarding margin stability.

Segmented View Reveals Diverse Opportunities Across Applications and Sources

A tissue-type perspective reveals a clear dichotomy between hematopoietic stem cells, sourced from bone marrow and peripheral blood, and mesenchymal stem cells, which originate from adipose tissue, bone marrow, and umbilical cord. Hematopoietic applications continue to benefit from established transplantation protocols, driving robust demand for peripheral blood-derived products, while bone marrow-harvested units remain the standard in certain transplant centers. Mesenchymal subtypes exhibit fast-growing interest in immune regulation and tissue repair, with adipose-derived variants favored for their high yield and umbilical cord sources prized for noninvasive collection and lower immunogenicity.

When viewed through the lens of application, cardiovascular indications such as myocardial infarction and peripheral arterial disease are advancing into late-stage trials, while immunotherapy segments including CAR-T, dendritic cell, and NK cell therapies have secured significant venture funding. Neurological targets address Alzheimer’s, multiple sclerosis, Parkinson’s, and spinal cord injury, representing a long-term growth opportunity despite complex neuroregulatory approvals. Orthopedic pursuits in bone regeneration, cartilage repair, and spine fusion continue to leverage scaffold integration, and wound healing efforts for burn wounds, chronic ulcers, and diabetic foot ulcers demonstrate strong preclinical results.

Source-based differentiation shows adipose, bone marrow, peripheral blood, and umbilical cord origins each presenting unique supply considerations and donor eligibility criteria. Product types-cryopreserved, freeze-dried, and fresh-span a spectrum of logistical trade-offs between shelf life, storage infrastructure, and immediate clinical availability. End users range from contract development and manufacturing organizations handling large-scale process workflows to hospitals and clinics administering therapies at bedside, as well as research institutes spearheading next-generation discovery. Distribution channels encompass direct sales relationships, distributor networks, and emerging online platforms that enable broader global reach and streamlined ordering processes.

Regional Dynamics Driving Global Adoption of Allogeneic Stem Cells

The Americas have solidified their leadership through substantial R&D investment, established reimbursement pathways, and an extensive network of clinical trial sites, making the region a primary launch market for novel allogeneic products. Evolving regulatory guidelines continue to balance expedited access with rigorous safety monitoring, creating a supportive environment for both domestic innovators and foreign entrants.

Europe, Middle East & Africa present a heterogeneous regulatory landscape, where countries like Germany and the United Kingdom are advancing accelerated approval schemes and dedicated cell therapy frameworks, while others maintain more conservative oversight. Market access strategies here hinge on navigating country-specific reimbursement formularies and forging alliances with regional health authorities to secure coverage and demonstrate value through real-world evidence.

Asia-Pacific is characterized by rapid adoption in markets such as Japan and South Korea, where early regenerative medicine laws have incentivized domestic development, and in China, where government-backed initiatives are scaling manufacturing infrastructure. Emerging markets across Southeast Asia and Oceania are poised for significant growth as regulatory harmonization efforts gain momentum and local capabilities expand.

Key Players Steering Innovation in Allogeneic Stem Cell Market

A cohort of leading biopharmaceutical and life science organizations has shaped the trajectory of allogeneic stem cell innovation. Lonza has expanded its commercial manufacturing footprint with multi-site cell processing facilities optimized for both hematopoietic and mesenchymal platforms. Thermo Fisher Scientific continues to integrate upstream and downstream workflows, offering turnkey solutions that streamline scale-up and regulatory compliance. STEMCELL Technologies has reinforced its position through specialized media formulations and analytical tools designed to accelerate process development.

Complementing these established providers, emerging pioneers are making strategic inroads. Companies focused on niche indications, such as immuno-oncology and neuroregeneration, have secured pivotal partnerships to advance cell therapies into late-stage trials. Meanwhile, contract development and manufacturing organizations are carving out dedicated allogeneic units, reflecting the increasing outsourcing trend among small and mid-sized developers. Collectively, these players are driving cost efficiencies, standardizing quality frameworks, and expanding geographic reach through collaborative networks.

Strategic Imperatives for Advancing Allogeneic Stem Cell Leadership

Industry leaders should prioritize investment in modular and scalable manufacturing technologies that can adapt to multiple allogeneic platforms, ensuring resilience against shifts in demand and regulatory standards. Collaborative ventures between biotechs, contract manufacturers, and academic institutions will accelerate technology transfer and optimize production throughput. Engaging proactively with regulatory authorities to shape evolving guidelines can reduce approval timelines and establish best practices that benefit the broader ecosystem.

To mitigate supply chain risks, organizations must diversify sourcing across both domestic and international vendors, implement strategic stockpiling of critical reagents, and explore localized production hubs to navigate tariff environments. Enhancing the value proposition through robust post-market surveillance and real-world outcome tracking will strengthen payer negotiations and support favorable reimbursement decisions. Finally, cultivating a skilled workforce with proficiency in advanced cell culture, analytical characterization, and quality assurance will underpin long-term competitiveness and innovation.

Rigorous Research Framework Underpinning Market Insights

This analysis draws upon a comprehensive framework combining primary and secondary research methodologies. In-depth interviews with industry executives, clinical investigators, and regulatory experts provided qualitative insights into market drivers, emerging applications, and policy developments. A rigorous review of peer-reviewed publications, patent filings, conference proceedings, and company disclosures supported the validation of technological trends and competitive strategies.

Quantitative data inputs were gathered from public financial reports, proprietary databases, and trade associations to map revenue streams, investment flows, and clinical trial volumes. Data triangulation techniques ensured consistency and reliability, while expert panels conducted peer reviews to refine key assumptions and contextualize findings. Regional nuances were captured through localized regulatory analyses and field surveys, resulting in a robust set of actionable market insights.

Synthesizing Insights for a Forward-Looking Perspective

The evolving landscape of allogeneic stem cells is defined by rapid scientific progress, shifting regulatory paradigms, and an expanding set of clinical applications. While challenges persist in manufacturing scalability, supply chain complexity, and reimbursement frameworks, the collective momentum across industry stakeholders signals a watershed moment for regenerative therapies. By synthesizing segmentation nuances, regional dynamics, tariff impacts, and competitive developments, this summary equips decision-makers with a holistic perspective on the opportunities that lie ahead.

As the field transitions from niche specialty care to broader clinical adoption, organizations that align their R&D agendas, manufacturing strategies, and market access plans with emerging trends will be best positioned to capture growth. The insights presented here serve as a foundation for strategic planning, partnership development, and resource allocation in an environment where agility and foresight are paramount.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Tissue Type
    • Hematopoietic Stem Cells
      • Bone Marrow
      • Peripheral Blood
    • Mesenchymal Stem Cells
      • Adipose Tissue
      • Bone Marrow
      • Umbilical Cord
  • Application
    • Cardiovascular
      • Myocardial Infarction
      • Peripheral Arterial Disease
    • Immunotherapy
      • CAR-T Therapies
      • Dendritic Cell Therapies
      • NK Cell Therapies
    • Neurological Disorders
      • Alzheimers Disease
      • Multiple Sclerosis
      • Parkinsons Disease
      • Spinal Cord Injury
    • Orthopedics
      • Bone Regeneration
      • Cartilage Repair
      • Spine Fusion
    • Wound Healing
      • Burn Wounds
      • Chronic Wounds
      • Diabetic Foot Ulcers
  • Source
    • Adipose Tissue
    • Bone Marrow
    • Peripheral Blood
    • Umbilical Cord
  • Product Type
    • Cryopreserved
    • Freeze Dried
    • Fresh
  • End-User
    • Contract Manufacturing Organizations
    • Hospitals and Clinics
    • Research Institutes
  • Distribution Channel
    • Direct Sales
    • Distributors
    • Online Channels
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Mesoblast Limited
  • Pluristem Therapeutics, Inc.
  • Athersys, Inc.
  • Gamida Cell Ltd.
  • Cynata Therapeutics Limited
  • Fate Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Celularity, Inc.
  • TiGenix N.V.
  • Osiris Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Allogeneic Stem Cells Market, by Tissue Type
8.1. Introduction
8.2. Hematopoietic Stem Cells
8.2.1. Bone Marrow
8.2.2. Peripheral Blood
8.3. Mesenchymal Stem Cells
8.3.1. Adipose Tissue
8.3.2. Bone Marrow
8.3.3. Umbilical Cord
9. Allogeneic Stem Cells Market, by Application
9.1. Introduction
9.2. Cardiovascular
9.2.1. Myocardial Infarction
9.2.2. Peripheral Arterial Disease
9.3. Immunotherapy
9.3.1. CAR-T Therapies
9.3.2. Dendritic Cell Therapies
9.3.3. NK Cell Therapies
9.4. Neurological Disorders
9.4.1. Alzheimers Disease
9.4.2. Multiple Sclerosis
9.4.3. Parkinsons Disease
9.4.4. Spinal Cord Injury
9.5. Orthopedics
9.5.1. Bone Regeneration
9.5.2. Cartilage Repair
9.5.3. Spine Fusion
9.6. Wound Healing
9.6.1. Burn Wounds
9.6.2. Chronic Wounds
9.6.3. Diabetic Foot Ulcers
10. Allogeneic Stem Cells Market, by Source
10.1. Introduction
10.2. Adipose Tissue
10.3. Bone Marrow
10.4. Peripheral Blood
10.5. Umbilical Cord
11. Allogeneic Stem Cells Market, by Product Type
11.1. Introduction
11.2. Cryopreserved
11.3. Freeze Dried
11.4. Fresh
12. Allogeneic Stem Cells Market, by End-User
12.1. Introduction
12.2. Contract Manufacturing Organizations
12.3. Hospitals and Clinics
12.4. Research Institutes
13. Allogeneic Stem Cells Market, by Distribution Channel
13.1. Introduction
13.2. Direct Sales
13.3. Distributors
13.4. Online Channels
14. Americas Allogeneic Stem Cells Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Allogeneic Stem Cells Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Allogeneic Stem Cells Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Mesoblast Limited
17.3.2. Pluristem Therapeutics, Inc.
17.3.3. Athersys, Inc.
17.3.4. Gamida Cell Ltd.
17.3.5. Cynata Therapeutics Limited
17.3.6. Fate Therapeutics, Inc.
17.3.7. Allogene Therapeutics, Inc.
17.3.8. Celularity, Inc.
17.3.9. TiGenix N.V.
17.3.10. Osiris Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ALLOGENEIC STEM CELLS MARKET MULTI-CURRENCY
FIGURE 2. ALLOGENEIC STEM CELLS MARKET MULTI-LANGUAGE
FIGURE 3. ALLOGENEIC STEM CELLS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ALLOGENEIC STEM CELLS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 89. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 90. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 92. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 94. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 95. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 96. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 97. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 98. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 109. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 171. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 173. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 184. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 186. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 188. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 206. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 207. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 208. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 210. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 212. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 213. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 214. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 215. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 219. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 223. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 226. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 227. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 228. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 275. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 279. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 280. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 297. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 298. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 299. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 301. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 302. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 303. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 304. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 305. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 306. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 310. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 311. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 312. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 314. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 315. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 317. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2030 (USD MILLION)
TABLE 318. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 319. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2

Companies Mentioned

The companies profiled in this Allogeneic Stem Cells market report include:
  • Mesoblast Limited
  • Pluristem Therapeutics, Inc.
  • Athersys, Inc.
  • Gamida Cell Ltd.
  • Cynata Therapeutics Limited
  • Fate Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Celularity, Inc.
  • TiGenix N.V.
  • Osiris Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 393.14 Million
Forecasted Market Value ( USD ) by 2030 $ 933.17 Million
Compound Annual Growth Rate19.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Allogeneic Stem Cells - Global Strategic Business Report - Product Image

Allogeneic Stem Cells - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Stem Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Allogeneic Stem Cell Therapies, Autologous Stem Cell Therapies), By Therapeutic Application (Oncology), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Stem Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Allogeneic Stem Cell Therapies, Autologous Stem Cell Therapies), By Therapeutic Application (Oncology), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Stem Cells Market by Product, Technology, Application, Cell Type, End User - Global Forecast to 2030 - Product Image

Stem Cells Market by Product, Technology, Application, Cell Type, End User - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Pipeline Insight, 2025 - Product Image

Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Market

Allogeneic stem cells are stem cells derived from a donor, typically from a family member, and used to treat a variety of diseases and conditions. Allogeneic stem cells are used in a variety of medical treatments, including bone marrow transplants, cancer treatments, and regenerative medicine. Allogeneic stem cells are also used in research to study the effects of stem cells on diseases and conditions. The allogeneic stem cell market is a rapidly growing field, with a variety of companies offering products and services related to stem cell research and treatments. Companies in the allogeneic stem cell market include Celgene, Novartis, and Osiris Therapeutics, which offer products and services related to stem cell research and treatments. Other companies in the market include BioTime, Athersys, and Mesoblast, which offer products and services related to stem cell therapies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.